Overview: Homovanillic Acid TestIntroduction: The Homovanillic Acid Test measures homovanillic acid (HVA) to diagnose neuroblastoma or adrenal tumors, causing weight loss or pain. Following 2023 ASCO guidelines, it uses immunoassays for high accuracy, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in clinical pathology for patients with suspected neuroendocrine tumors.
Other Names: HVA Urine Assay, Neuroblastoma Screening Test.
FDA Status: Laboratory-developed test (LDT), meeting clinical pathology standards for diagnostic accuracy.
Historical Milestone: HVA testing began in the 1970s with neuroblastoma research. Immunoassay-based methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Measures HVA to diagnose neuroblastoma or adrenal tumors, guides treatment, and evaluates patients with weight loss or pain.
Test Parameters: 1. Homovanillic Acid
Pretest Condition: No fasting required. Collect urine (spot or 24-hour) at any time. Report symptoms like weight loss, abdominal pain, or family history of neuroendocrine tumors.
Specimen: 5-20 mL urine (sterile container) or 50-100 mL 24-hour urine (sterile container). Transport in a biohazard bag within 2 hours.
Sample Stability at Room Temperature: 2 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: Not frozen
Medical History: Document weight loss, abdominal pain, or family history of neuroblastoma or adrenal tumors. Include current medications and recent symptoms.
Consent: Written consent required, detailing the tests purpose, cancer diagnostic implications, and potential need for oncology treatment.
Procedural Considerations: Uses immunoassays to measure HVA levels. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for cancer screening.
Factors Affecting Result Accuracy: Improper sample collection, contamination, or certain medications (e.g., L-dopa) can affect results. Incomplete 24-hour urine collection may reduce accuracy.
Clinical Significance: Elevated HVA suggests neuroblastoma or adrenal tumors, guiding imaging or biopsy. Normal levels may require further tumor marker testing.
Specialist Consultation: Consult an oncologist or pediatric oncologist for result interpretation and treatment planning.
Additional Supporting Tests: VMA, catecholamines, or imaging (e.g., CT/MRI) to confirm neuroendocrine tumors.
Test Limitations: HVA is not specific to neuroblastoma; clinical correlation is needed. Dietary factors may influence results.
References: ASCO Neuroblastoma Guidelines, 2023; Journal of Clinical Oncology, Brodeur GM, 2022.
